Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

e company reiterated its 2009 financial guidance for revenue and operating expenses initially provided on February 26, 2009.

Revenue

Revenue for 2009, including Actimmune(R) and anticipated milestone payments from Roche, is expected to be in a range of approximately $40 to $50 million. Actimmune revenue represents approximately 50% of this revenue range.

Operating Expenses

R&D expense is anticipated to be in a range of approximately $90 to $100 million, net of development cost reimbursements under the Roche collaboration. Of this amount, approximately 60% is attributed to pirfenidone which includes expenses for CAPACITY, RECAP, the preparation and support of NDA and MAA submissions and manufacturing.

Approximately 35% of the R&D expense is attributed to the company's one-third share of all development expenses incurred by the collaboration with Roche on ITMN-191. The balance of 2009 R&D expense is related to the advancement of a named pirfenidone analog compound, ITMN-520, toward an expected IND filing in mid-2010.

G&A expense is anticipated to be in a range of approximately $35 to $40 million. The G&A guidance range includes approximately $5.0 million of various pirfenidone pre-marketing costs and a similar amount in legal fees associated with a DOJ action against a former InterMune executive covered by an indemnification agreement.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for the first quarter 2009, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 95970767. A replay of the webcast and teleconference will be available approximately three hours
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Yuma Regional Cancer Center ... therapies brings comprehensive cancer care to Yuma, Arizona. ... Cancer Center has officially opened. A Mayo Clinic ... services such as open, semi-private and private infusion ... Society Resource Center, hematology, rehabilitation center, a pain ...
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
(Date:7/30/2014)... CT (PRWEB) July 30, 2014 Connecticut ... development organization based in East Hartford, Conn., was awarded ... Phase II of a project that will determine the ... in rural north-central Connecticut. USDA Rural Development provided $53,000 ... program for the second phase of the feasibility study ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 LayerBio, ... announces completion of its first round of seed financing ... will enable preliminary efforts to develop a novel sustained-release ... support of our investors and their commitment to this ... of LayerBio. "Ophthalmology is one of many areas in ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Inc., a privately held molecular diagnostics company developing innovative ... announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. ... Metamark with over 20 years of experience in cancer ... Dr. Blume-Jensen was department head at EMD Serono, Inc. ...
... 16 Cord Blood America, Inc . ( ... the umbilical cord blood stem cell preservation company ... stem cells, a biological insurance policy, to families nationwide ... and CEO, was interviewed by analyst Francis Gaskins on ...
... LOUIS, Sept. 15 Sigma-Aldrich Corporation (Nasdaq: SIAL ... Healthcare Conference on Tuesday, September 21st at 12:30 PM ET ... audio broadcast over the Internet available at http://investor.sigmaaldrich.com/ . ... About Sigma-Aldrich: Sigma-Aldrich is ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Scientific Officer 2Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, 'Afford-A-Cord,' and Profitability 2
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... 2014 NexID Biometrics , a ... solutions for the biometric authentication industry, has recently ... online authentication with standards for strong authentication. According ... decision to join FIDO Alliance stems from NexID,s ... use. We believe the FIDO Alliance is a ...
(Date:7/30/2014)... how to create colors, nature had already perfected the ... different hues, for example. Now scientists are tapping into ... to make colored plastics. Their paper on using structure ... rather than dyes, to produce color appears in the ... Mortensen, Anders Kristensen and colleagues point out that currently, ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2NexID Biometrics Joins the FIDO Alliance 2
... Medicine have discovered a technique that directly converts skin ... patients with multiple sclerosis, cerebral palsy and other so-called ... in the journal Nature Biotechnology . This ... which provide a vital sheath of insulation that protects ...
... 14, 2013)Stenting reopens completely blocked bowel arteries, preventing ... causes individuals severe pain and leads to excessive ... Society of Interventional Radiology,s 38th Annual Scientific Meeting ... mesenteric arteries saves lives," said Daniel A. Leung, ...
... mechanism that causes a slime to form, making bacteria ... under threat, some bacteria can shield themselves in a ... made up of communities of bacteria held together to ... and sinusitis; in healthcare, biofilms can lead to life ...
Cached Biology News:Ordinary skin cells morphed into functional brain cells 2Stenting blocked bowel arteries saves lives 2Secrets of bacterial slime revealed 2
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Biology Products: